CV Therapeutics Again Declines Astellas $16 Per Share Purchase Offer
This article was originally published in PharmAsia News
Executive Summary
Less than a month after Astellas made public its bid to purchase CV Therapeutics for $16 a share for a total price of nearly $1 billion, CVT turned down the offer Feb. 20 as "significantly undervaluing" the biotech and not serving the best interests of the company or its stockholders
You may also be interested in...
CVT And Gilead Look To Lock Out Astellas With Planned Merger
Market reaction was mixed but CV Therapeutics and Gilead threw a shock into the current pharma/biotech merger and acquisition frenzy as Gilead sought to trump Astellas' months-long bid to acquire CVT with its own bid of $20 per share. The deal's estimated total value is $1.4 billion
CVT And Gilead Look To Lock Out Astellas With Planned Merger
Market reaction was mixed but CV Therapeutics and Gilead threw a shock into the current pharma/biotech merger and acquisition frenzy as Gilead sought to trump Astellas' months-long bid to acquire CVT with its own bid of $20 per share. The deal's estimated total value is $1.4 billion
Astellas Turns Up Heat On Bid To Acquire CV Therapeutics
Following CV Therapeutics' refusal to accept its $16 per share purchase bid, Astellas is trying to turn up the pressure on CVT with a two-pronged approach involving both a tender offer for outstanding shares and a lawsuit in Delaware Chancery Court